Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study.

PURPOSE To determine the safety and efficacy of ferumoxtran 10-enhanced magnetic resonance (MR) imaging for diagnosis of metastases to lymph nodes and the clinical usefulness of ferumoxtran 10 in nodal staging. MATERIALS AND METHODS One hundred fifty-two patients were injected with ferumoxtran 10. Readers independently evaluated precontrast MR images by using node size criteria and subjective assessment of other imaging features. Ferumoxtran 10-enhanced MR images were evaluated alone and paired with precontrast images for comparison. The diagnostic performances of precontrast MR size criteria and postcontrast MR imaging were evaluated with receiver operating characteristic (ROC) analysis. Lymph node signal intensity was correlated with histopathologic findings. MR imaging and histopathologic nodal stages were compared. RESULTS Node-level sensitivity, specificity, and accuracy of precontrast MR imaging were 54%, 82%, and 68%, respectively, with node size criterion alone; 91%, 51%, and 71%, respectively, with subjective reader assessment; 85%, 85%, and 85%, respectively, with postcontrast MR imaging alone; and 83%, 77%, and 80%, respectively, with paired pre- and postcontrast MR imaging. Compared with size criteria, subjective reader assessment had higher sensitivity but substantially lower specificity. Areas under the ROC curve for pre- and postcontrast MR imaging were 0.76 and 0.83, respectively. Nonmetastatic nodes had significantly lower signal intensity than metastatic nodes on postcontrast T2-weighted MR images (P <.001). Postcontrast nodal staging was significantly more accurate than precontrast nodal staging (P <.01). Headache, back pain, vasodilatation, and urticaria each occurred in 6% of patients. CONCLUSION Ferumoxtran 10-enhanced MR imaging was safe and effective and facilitated improved diagnostic performance. Use of iron oxide-enhanced MR imaging increased the positive predictive value by 20% and the accuracy by 14% compared with reader assessment. Differentiating patients with no nodal metastatic involvement was more reliable with ferumoxtran 10-enhanced MR imaging than with precontrast MR imaging.

[1]  G. Marchal,et al.  Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) – results of a phase-III multicenter clinical trial , 2002, European Radiology.

[2]  James I. Cohen,et al.  Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. , 2002, AJNR. American journal of neuroradiology.

[3]  P. Hudgins,et al.  Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. , 2002, AJNR. American journal of neuroradiology.

[4]  H. Pannu,et al.  MR imaging of mediastinal lymph nodes: Evaluation using a superparamagnetic contrast agent , 2000, Journal of magnetic resonance imaging : JMRI.

[5]  R. Carrau,et al.  Selective Neck Dissection in the Management of the Clinically Node‐Negative Neck , 2000, The Laryngoscope.

[6]  G. Frija,et al.  MR lymphography using iron oxide nanoparticles in rats: Pharmacokinetics in the lymphatic system after intravenous injection , 2000, Journal of magnetic resonance imaging : JMRI.

[7]  W. Yuh,et al.  Functional Magnetic Resonance Imaging Using Iron Oxide Particles in Characterizing Head and Neck Adenopathy , 2000, The Laryngoscope.

[8]  R Weissleder,et al.  Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. , 2000, Radiology.

[9]  B. Thompson,et al.  Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma , 1999, Journal of magnetic resonance imaging : JMRI.

[10]  R Weissleder,et al.  MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. , 1999, AJR. American journal of roentgenology.

[11]  R. Edelman,et al.  Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran‐10: Phase II clinical trial data , 1999 .

[12]  R. Edelman,et al.  Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data. , 1999, Journal of magnetic resonance imaging : JMRI.

[13]  D Jacqmin,et al.  Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. , 1998, Radiology.

[14]  W. Ball.  Neuroimaging in brain death. , 1998, AJNR. American journal of neuroradiology.

[15]  G. Snow,et al.  The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: how reliable is it? , 1998, AJNR. American journal of neuroradiology.

[16]  B J McNeil,et al.  Comparison of CT and MR Imaging in Staging of Neck , 2005 .

[17]  B. J. Bailey.  Selective neck dissection: the challenge of occult metastases. , 1998, Archives of otolaryngology--head & neck surgery.

[18]  N H Terry,et al.  Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue? , 1998, Head & neck.

[19]  W. Dillon.  Cervical nodal metastases: another look at size criteria. , 1998, AJNR. American journal of neuroradiology.

[20]  J. Johnson.  Selective neck dissection in patients with squamous cell carcinoma of the upper respiratory and digestive tracts: a lack of adequate data. , 1998, Archives of otolaryngology--head & neck surgery.

[21]  M. Harisinghani,et al.  MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (combidex): Preliminary observations , 1997, Journal of magnetic resonance imaging : JMRI.

[22]  R. Castellino,et al.  Characterization of Reactive Versus Tumor-Bearing Lymph Nodes with Interstitial Magnetic Resonance Lymphography in an Animal Model , 1995, Investigative radiology.

[23]  C Zimmer,et al.  MR imaging of phagocytosis in experimental gliomas. , 1995, Radiology.

[24]  S E Seltzer,et al.  Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. , 1995, Radiology.

[25]  Hong Wang,et al.  Investigation of Mechanisms Influencing the Accumulation of Ultrasmall Superparamagnetic Iron Oxide Particles in Lymph Nodes , 1995, Investigative radiology.

[26]  W. Yuh,et al.  Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. , 1994, Radiology.

[27]  A. Olukotun,et al.  Phase I clinical evaluation of a new iron oxide MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[28]  R Weissleder,et al.  MR lymphography: study of a high-efficiency lymphotrophic agent. , 1994, Radiology.

[29]  H. Bengele,et al.  Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration. , 1994, Magnetic resonance imaging.

[30]  G. Frija,et al.  MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. , 1994, AJR. American journal of roentgenology.

[31]  A. Darkazanli,et al.  MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. , 1992, AJR. American journal of roentgenology.

[32]  B. Hamm,et al.  MR lymphography with iron oxide particles: dose-response studies and pulse sequence optimization in rabbits. , 1992, AJR. American journal of roentgenology.

[33]  R. Weissleder,et al.  Lymph nodes: microstructural anatomy at MR imaging. , 1991, Radiology.

[34]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. , 1990, Radiology.

[35]  R Weissleder,et al.  Experimental lymph node metastases: enhanced detection with MR lymphography. , 1989, Radiology.